Biomarkers in Patients With Stage III or Stage IV Follicular Lymphoma Treated on Clinical Trial E-1496
Recruitment status was Active, not recruiting
RATIONALE: Studying samples of tissue from patients with cancer in the laboratory may help doctors identify and learn more about biomarkers related to cancer. It may also help doctors predict how patients respond to treatment.
PURPOSE: This laboratory study is looking at biomarkers in patients with stage III or stage IV follicular lymphoma treated on clinical trial E-1496.
Genetic: gene expression analysis
Genetic: microarray analysis
Genetic: polymorphism analysis
Other: diagnostic laboratory biomarker analysis
Other: immunohistochemistry staining method
Other: immunologic technique
|Official Title:||Identification of Biomarkers in Follicular Lymphoma|
- Correlation of gene expression profiles with progression-free survival (PFS) [ Designated as safety issue: No ]
- Prediction of PFS by immunoglobulin Fc-gamma receptor polymorphisms as assessed by immunohistochemistry [ Designated as safety issue: No ]
- Assessment of significance of microenvironment by constructing tissue microarrays and immunostaining with relevant biomarkers [ Designated as safety issue: No ]
- Correlation of relevant biomarkers with clinical features, response, and PFS [ Designated as safety issue: No ]
|Study Start Date:||April 2007|
- Correlate gene expression profiles with progression-free survival (PFS) of patients with stage III or IV follicular lymphoma treated with cyclophosphamide, vincristine, and prednisone with or without rituximab on clinical trial E-1496.
- Determine if immunoglobulin Fc-gamma receptor polymorphisms are predictive of PFS in these patients.
- Assess the significance of the microenvironment by constructing tissue microarrays of follicular lymphoma and immunostaining with relevant biomarkers.
- Correlate relevant biomarkers with clinical features, response, and PFS.
OUTLINE: This is a multicenter study.
Tissue samples are analyzed by gene expression profiling, microarrays to predict gene expression, immunohistochemistry, and immunoglobulin Fc-gamma receptor polymorphism analysis for biological markers.
PROJECTED ACCRUAL: A total of 175 samples will be accrued for this study.
Please refer to this study by its ClinicalTrials.gov identifier: NCT00898963
|Study Chair:||Randall D. Gascoyne, MD||British Columbia Cancer Agency|